The latest price target for Seelos Therapeutics (NASDAQ:SEEL) was reported by Guggenheim on September 22, 2023. The analyst firm set a price target for $0.00 expecting SEEL to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Seelos Therapeutics (NASDAQ:SEEL) was provided by Guggenheim, and Seelos Therapeutics downgraded their neutral rating.

The last upgrade for Seelos Therapeutics Inc happened on September 27, 2021 when Roth Capital raised their price target to $8. Roth Capital previously had a neutral for Seelos Therapeutics Inc.

The last downgrade for Seelos Therapeutics Inc happened on September 22, 2023 when Guggenheim changed their price target from N/A to N/A for Seelos Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seelos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seelos Therapeutics was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.

While ratings are subjective and will change, the latest Seelos Therapeutics (SEEL) rating was a downgraded with a price target of $0.00 to $0.00. The current price Seelos Therapeutics (SEEL) is trading at is $0.21, which is out of the analyst’s predicted range.